Quick Answer
Matinas BioPharma Holdings, Inc. reported Revenue (ASC 606) of $1.10 million for fiscal year 2023.
Matinas BioPharma Holdings, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $1.10M | -65.6% |
| 2022 | $3.19M | +9560.6% |
| 2021 | $33.0K | -79.2% |
| 2020 | $158.3K | +76.3% |
| 2019 | $89.8K | -25.0% |
| 2018 | $119.8K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $1.10M | — | +3.1% |
| September 30, 2022 | $1.06M | — | +0.0% |
| June 30, 2022 | $1.06M | — | +3089.0% |
| March 31, 2021 | $33.3K | — | -65.2% |
| September 30, 2020 | $95.8K | — | +6.7% |
| June 30, 2019 | $89.8K | — | — |
- Matinas BioPharma Holdings, Inc. showed a decrease of -65.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2023 period, Matinas BioPharma Holdings, Inc.’s revenue (asc 606) has grown by 815.2% (from $119.8 thousand to $1.10 million).
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: